These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 14507992)

  • 1. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy.
    McMullen JR; Shioi T; Zhang L; Tarnavski O; Sherwood MC; Kang PM; Izumo S
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12355-60. PubMed ID: 14507992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.
    McMullen JR; Amirahmadi F; Woodcock EA; Schinke-Braun M; Bouwman RD; Hewitt KA; Mollica JP; Zhang L; Zhang Y; Shioi T; Buerger A; Izumo S; Jay PY; Jennings GL
    Proc Natl Acad Sci U S A; 2007 Jan; 104(2):612-7. PubMed ID: 17202264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy.
    McMullen JR; Izumo S
    Novartis Found Symp; 2006; 274():90-111; discussion 111-7, 152-5, 272-6. PubMed ID: 17019808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction.
    Weeks KL; Gao X; Du XJ; Boey EJ; Matsumoto A; Bernardo BC; Kiriazis H; Cemerlang N; Tan JW; Tham YK; Franke TF; Qian H; Bogoyevitch MA; Woodcock EA; Febbraio MA; Gregorevic P; McMullen JR
    Circ Heart Fail; 2012 Jul; 5(4):523-34. PubMed ID: 22705768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
    Weeks KL; Tham YK; Yildiz SG; Alexander Y; Donner DG; Kiriazis H; Harmawan CA; Hsu A; Bernardo BC; Matsumoto A; DePinho RA; Abel ED; Woodcock EA; McMullen JR
    Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1470-H1485. PubMed ID: 33577435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
    Luo J; McMullen JR; Sobkiw CL; Zhang L; Dorfman AL; Sherwood MC; Logsdon MN; Horner JW; DePinho RA; Izumo S; Cantley LC
    Mol Cell Biol; 2005 Nov; 25(21):9491-502. PubMed ID: 16227599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload.
    Harris IS; Zhang S; Treskov I; Kovacs A; Weinheimer C; Muslin AJ
    Circulation; 2004 Aug; 110(6):718-23. PubMed ID: 15289381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.
    Rigor DL; Bodyak N; Bae S; Choi JH; Zhang L; Ter-Ovanesyan D; He Z; McMullen JR; Shioi T; Izumo S; King GL; Kang PM
    Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H566-72. PubMed ID: 19122165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway.
    McMullen JR; Shioi T; Huang WY; Zhang L; Tarnavski O; Bisping E; Schinke M; Kong S; Sherwood MC; Brown J; Riggi L; Kang PM; Izumo S
    J Biol Chem; 2004 Feb; 279(6):4782-93. PubMed ID: 14597618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signaling.
    De Blasio MJ; Huynh K; Qin C; Rosli S; Kiriazis H; Ayer A; Cemerlang N; Stocker R; Du XJ; McMullen JR; Ritchie RH
    Free Radic Biol Med; 2015 Oct; 87():137-47. PubMed ID: 25937176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling.
    Bernardo BC; Weeks KL; Pongsukwechkul T; Gao X; Kiriazis H; Cemerlang N; Boey EJH; Tham YK; Johnson CJ; Qian H; Du XJ; Gregorevic P; McMullen JR
    Clin Sci (Lond); 2018 Feb; 132(3):381-397. PubMed ID: 29358507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes.
    Ritchie RH; Love JE; Huynh K; Bernardo BC; Henstridge DC; Kiriazis H; Tham YK; Sapra G; Qin C; Cemerlang N; Boey EJ; Jandeleit-Dahm K; Du XJ; McMullen JR
    Diabetologia; 2012 Dec; 55(12):3369-81. PubMed ID: 23001375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular signal-regulated kinase (ERK) activation preserves cardiac function in pressure overload induced hypertrophy.
    Mutlak M; Schlesinger-Laufer M; Haas T; Shofti R; Ballan N; Lewis YE; Zuler M; Zohar Y; Caspi LH; Kehat I
    Int J Cardiol; 2018 Nov; 270():204-213. PubMed ID: 29857938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway.
    Song HK; Kim J; Lee JS; Nho KJ; Jeong HC; Kim J; Ahn Y; Park WJ; Kim DH
    PLoS One; 2015; 10(3):e0122251. PubMed ID: 25826393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Puerarin attenuates pressure overload-induced cardiac hypertrophy.
    Yuan Y; Zong J; Zhou H; Bian ZY; Deng W; Dai J; Gan HW; Yang Z; Li H; Tang QZ
    J Cardiol; 2014 Jan; 63(1):73-81. PubMed ID: 23906530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.
    Perrino C; Naga Prasad SV; Mao L; Noma T; Yan Z; Kim HS; Smithies O; Rockman HA
    J Clin Invest; 2006 Jun; 116(6):1547-60. PubMed ID: 16741575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.
    McMullen JR; Shioi T; Zhang L; Tarnavski O; Sherwood MC; Dorfman AL; Longnus S; Pende M; Martin KA; Blenis J; Thomas G; Izumo S
    Mol Cell Biol; 2004 Jul; 24(14):6231-40. PubMed ID: 15226426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
    Clemente CF; Xavier-Neto J; Dalla Costa AP; Consonni SR; Antunes JE; Rocco SA; Pereira MB; Judice CC; Strauss B; Joazeiro PP; Matos-Souza JR; Franchini KG
    J Mol Cell Cardiol; 2012 Feb; 52(2):493-501. PubMed ID: 22056317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy.
    Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K
    Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.